Journal of Cellular Signaling
ISSN: 2692-0638

Commentary - Journal of Cellular Signaling (2020) Volume 1, Issue 3

Kv1.3 Potassium Channels: Promising Therapeutic Targets in Hematological Malignancies

Theresa Lowinus1, Tanima Bose2, Luca Simeoni3, Burkhart Schraven3, Ursula Bommhardt3*

1Department of Hematology, Oncology, and Stem Cell Transplantation, Freiburg University Medical Center, Faculty of Medicine, Freiburg, Germany

2Institute for Clinical Neuroimmunology, Ludwigs-Maximilians-University (LMU), Munich, Germany

3Institute of Medical and Clinical Immunology, Health Campus Immunology, Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany

*Corresponding Author:
Ursula Bommhardt
E-mail: Ursula.Bommhardt@med.ovgu.de

Received date: July 10, 2020; Accepted date: July 30, 2020

Citation: Lowinus T, Bose T, Simeoni L, Schraven B, Bommhardt U. Kv1.3 Potassium Channels: Promising Therapeutic Targets in Hematological Malignancies. J Cell Signal 2020; 1(3): 79-86.

Copyright: © 2020 Lowinus T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Abstract

Voltage-gated Kv1.3 potassium channels control the membrane potential, cellular activation and cell death. Kv1.3 channels have been extensively studied in autoimmune disorders and are promising drug targets for the treatment of solid cancer. However, licensed drugs for specific inhibition of Kv1.3 channels in vivo are not available. Here, we give a short overview of the main characteristics of Kv1.3 channels and then focus on recent advances in the use of Kv1.3 blockers in the treatment of hematological malignancies, proposing memantine as a valuable Kv1.3 channel inhibitor for clinical application.


Keywords

Kv1.3 channel, Lymphoid leukemia, Myeloid leukemia, Memantine, Cell death


Kv1.3 Channels

Voltage-gated potassium channels (Kv) are selectively permeable for potassium ions and are activated by change of the cell membrane voltage [1]. They are grouped into 12 subfamilies (Kv1-Kv12) with the Kv1 subfamily named Shaker type. Kv channels consist of a homotetramer with four α-subunits and a central ion pore. Each α-subunit is composed of six transmembrane domains S1-S6, S4 serving as voltage-gate, S5 and S6 forming the p-loop as selective potassium ion filter. The α-subunits are associated with regulatory subunits such as Kvß, which control channel expression, gating, and potassium current, with integrins [2] and with adapter proteins and protein tyrosine kinase p56lck, which are involved in signal transduction [3]. Initially studied in excitable cells like neurons, expression of Kv channels was detected in different cell types including hematopoietic cells, and Kv channels of the Kv1.3 type were firstly described in human T lymphocytes in 1984 [4,5]. Kv1.3 channels of the plasma membrane prevent accidental depolarization of the T-cell, thereby regulating its resting membrane potential. Upon T-cell receptor engagement, Kv1.3 channels are recruited into the immunological synapse [6] and via potassium efflux prevent continuous depolarization generated by calcium influx through calcium release-activated calcium (CRAC) channels. The permissive hyperpolarization is crucial for sustained calcium influx to allow effective T-cell activation [7]. Elegant studies have shown that Kv1.3 channels are also expressed in the mitochondrial membrane (mitoKv1.3), where they function as mediators of the intrinsic apoptosis pathway [8]. Upon an initial apoptotic stimulus, the pro-apoptotic Bcl-2 family member Bax, which is located in the outer mitochondrial membrane, translocates to the mitoKv1.3 and blocks its central channel pore at Lysin128. Inhibition of mitoKv1.3 channels results in mitochondrial hyperpolarization, enhanced production of reactive oxygen species (ROS) and the release of cytochrome C (CytC), which feeds into the activation of Caspase-9 and Caspase-3 [9]. In addition, Kv1.3 channels have been found to be located in the nuclear membrane of some cancer cell lines, including Jurkat cells [10], but their functional role in the nuclear compartment needs to be unraveled. Kv1.3 channels have been extensively studied in autoimmune disorders [11] and are expected to be promising pharmacological targets for the treatment of solid cancer [12].


Blockade of Kv1.3 Channels

Inhibitors of Kv1.3 channels are classified into peptide toxins and low molecular weight blockers [11]. Peptide toxins comprise scorpion toxins (for instance Vm24 [13] and MgTX [14]) and sea anemone toxins (like ShK [15]) and their derivatives with a size of ~4 kDa. They block the Kv1.3 channel pore with high affinity and selectivity independent of the open probability of the channel. Due to their positive charge, peptide toxins are membrane-impermeable and thus block Kv1.3 channels of the plasma membrane, but not apoptosis-mediating mitoKv1.3 channels. Furthermore, they can cause allergic reactions and need to be applied parenterally. Dalazatide is the first derivative tested in clinical phase I/II trials on healthy volunteers and patients with psoriasis [16]. Other peptide toxins are used for research purposes only. Low molecular weight blockers are characterized by a size below 0.8 kDa and include psoralen derivatives, such as 5-(4-phenylobutoxy) psoralen (Psora-4) and 5-(4-phenoxybutoxy) psoralen (PAP-1, [17]), and clofazimine, a drug applied in the treatment of leprosy [18]. Due to their hydrophobicity, low molecular weight blockers are membrane-permeable and thus are able to block mitoKv1.3 channels to induce apoptosis. Compared to peptide toxins, they have a higher bioavailability, but show a reduced affinity and selectivity [12]. Whereas structural similarities of Kv1.3 channel blockers have not been identified, detailed analyses are available for Kv1.3 channels. Interestingly, the structure of Kv1.3 channels is closely related to ionotropic glutamate receptors (iGluR) showing a significant amino acid homology in the channelforming units. Specifically, the p-loop and S5/S6 domains of Kv1.3 channels structurally resemble the M2 and M1/ M3 domains of iGluR, respectively [19]. Recently, we showed that memantine, a licensed antagonist of iGluRs of the N-methyl-D-aspartate type (NMDARs), also inhibits Kv1.3 channel currents of lymphocytes [20,21].

Despite immense progress in the therapy of hematological malignancies, treatment of acute leukemia remains challenging as many patients show relapses or do not tolerate intensive therapeutic regimens. Patients suffering from chronic hematological diseases, such as lymphoma or chronic myeloid leukemia (CML), often require long-term treatment and the reduction of therapy-associated toxicity is of particular challenge. Given that Kv1.3 channels regulate proliferation and cell death of lymphocytes, Kv1.3 channels present attractive oncological targets in fighting hematological neoplasia [22], however, licensed drugs for specific inhibition of Kv1.3 channels in vivo are not available.


Kv1.3 Channels in Lymphocytic Leukemia and Lymphoma

Acute T-lymphoblastic leukemia (T-ALL) and T-cell lymphoma are rare but highly aggressive diseases with restricted therapeutic options. Using memantine to pharmacologically block Kv1.3 channels, we recently demonstrated that inactivation of Kv1.3 channels by memantine potentiates cytarabine (AraC)-induced cell death of T-ALL cell lines (Jurkat and CEM) as well as patients’ primary T leukemic blasts. On the molecular level, memantine co-application promoted a concurrent inhibition of the central AKT, ERK1/2 and c-MYC signaling pathways. In addition, it augmented mitochondrial CytC release and activation of Caspase-9 and Caspase-3. These data propose that in combination with AraC, blockade of Kv1.3 channels by memantine, a licensed and safe drug, may be a therapeutic option for the treatment of T-ALL [23]. Consistent with our data, another report showed that treatment of Jurkat cells with the mitoKv1.3 channel inhibitor PCARBTP, a derivative of the low molecular weight blocker PAP-1, reduced basal and TCR/CD3- induced activation of the signaling molecules ZAP70, PI-3-K, AKT, and JNK. Inhibition of PI-3-K and AKT sensitized Jurkat cells to PCARBTP and allowed induction of cell death at lower drug concentrations [24]. These data are promising, but possible toxic side effects of PCARBTP still need clinical evaluation. Expression of functional Kv1.3 channels was also reported for primary malignant T-cells isolated from patients with Mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma, and from patients with Sézary syndrome, a leukemic progress of MF. Kv1.3 blockade by the peptide toxins ShK and Vm24 inhibited proliferation, IL-9 production and CD25 induction of the malignant T-cells, but the peptide toxins had no effect on cell death of Sézary cells [25,26]. Thus, Kv1.3 channel inhibition provides potential to combat neoplastic T-cells in Sézary syndrome. However, peptide toxins are not membrane-permeable, and inhibition of apoptosis-regulating mitoKv1.3 channels may be required for killing malignant Sézary cells.

Kv1.3 channels, although most intensely studied in T-cells, are also critical for B-cell function [27]. We previously showed that blockade of Kv1.3 currents by memantine diminishes BCR-induced calcium flux and inhibits B-cell proliferation, antibody production, and migration [21]. Memantine also blocks Kv1.3 channels of Raji Burkitt-lymphoma cells and preliminary results suggest that memantine enhances AraC-induced cell death of primary B acute lymphoblastic leukemia (B-ALL) cells (Figures 1A and 1B) comparable to the effects observed for T-ALL cells [23]. These results indicate that memantine may be suited for Kv1.3 blockade in B-ALL and B-lymphoma treatments, but more detailed studies are required. Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic mature B cells, which are resistant to apoptosis. Neoplastic B cells showed higher expression of Kv1.3 channels than healthy B cells, which was linked to oncogenic B-RAF signaling. Inhibition of Kv1.3 channels was proposed as a novel therapeutic strategy to induce cell death of CLL cells while sparing healthy B cells. Whereas the membrane-permeant Kv1.3 channel inhibitors Psora-4, PAP-1, and clofazimine efficiently induced cell death of CLL cells, even in the presence of mesenchymal stem cells, neoplastic B cells were resistant to the membraneimpermeant Kv1.3 channel blocker ShK, indicating that inhibition of mitoKv1.3 is required for apoptosis induction [28,29]. As Kv1.3 channel inhibition effectively killed >98% of primary CLL cells ex vivo independent of the p53 status, it may also be a promising therapeutic option for the group of p53-mutated CLL patients which shows lower response rates and shorter progressionfree survival to established therapies compared to p53- wildtype CLL patients [30]. Fludarabine, a purine analog commonly used in the treatment of CLL, was found to block Kv1.3 channel currents of malignant B-cell lines at concentrations achieved in the plasma of treated patients [31]. Also, rituximab, an anti-CD20 monoclonal antibody regularly used to treat CLL and other B-cell lymphoma, was shown to inhibit Kv1.3 channels in B-lymphoma cell lines. The effect of rituximab on Kv1.3 channels was abolished after selective blockade of FcγRIIB receptors and rituximab-induced apoptosis of neoplastic B cells was attenuated by blockade of FcγRIIB receptors and partially mimicked by inhibition of Kv1.3 channels [32]. Thus, a Kv1.3 channel blockade may in part account for the therapeutic effects of fludarabine and rituximab in CLL treatment.


Kv1.3 Channels in Myeloid Leukemia

Detailed studies of Kv1.3 channel expression and function in healthy and malignant T and B lymphoid cells provide an excellent basis for Kv1.3 channel inhibition strategies to treat lymphoid neoplasia. In contrast, less is known about Kv1.3 channels in myeloid cells. Kv1.3 mRNA transcripts were detected in CD34+ hematopoietic stem cells of human blood [33]. We reported functional Kv1.3 channel expression in acute myeloid leukemia (AML) cells using whole-cell patch-clamp technique. Kv1.3 channel currents were inhibited by memantine and AraC-induced cell death of several AML cell lines and primary AML blasts from patients, including FLT3- ITD mutant AML, was potentiated by memantine cotreatment. Inhibition of AKT and ERK1/2 signaling and augmented mitochondrial CytC release was observed upon combined drug treatment, indicating that related cell death mechanisms are initiated in AML and T-ALL cells [23]. Based on the concept that inhibition of mitoKv1.3 induces intrinsic apoptosis [34], in AraC/memantine co-treatment of acute leukemia cells AraC may act as an initial apoptotic stimulus inducing translocation of Bax to mitoKv1.3 channels and memantine may enhance mitochondrial CytC release through further inhibition of mitoKv1.3 channels. This hypothesis assumes that memantine is membrane-permeable and enters the cell, which has not been investigated though. However, memantine is a hydrophobic molecule and crosses the blood-brain barrier, suggesting that memantine can act on intracellular Kv1.3 channels (mitoKv1.3 and possibly nuclear Kv1.3). Janus-kinase 2 (JAK2) is a tyrosine kinase involved in cytokine and growth factor signaling and plays a central role in proliferation and differentiation of immune cells. The frequently occurring gain-of-function JAK2 V617F mutation gives rise to a constitutively active JAK2 kinase and can drive the pathogenesis of myeloproliferative neoplasms (MPN) [35]. Since JAK2 regulates Kv1.3 channel activity and protein expression [36], Kv1.3 channels may be promising drug targets for treating MPN. Recently, it was shown that clofazimine induces apoptosis of blood mononuclear cells and CD34+ progenitor cells of CML patients and synergizes with imatinib, a protein tyrosine kinase inhibitor commonly used in CML therapy. Hematopoietic progenitor cells from healthy donors were not affected. The authors demonstrated that clofazimine induces peroxisome proliferator-activated receptor-γ (PPARγ)-mediated apoptosis in CML cells via induction of ROS and activation of Caspase-9 and Caspase-3 [37]. Since clofazimine inhibits Kv1.3 channels and induces similar cell death mechanisms in other neoplastic cells [28], Kv1.3 channel inhibition may contribute to the clofazimine-mediated cell death in CML cells.


Kv1.3 Channels and Memantine

Kv1.3 channels are not only expressed in immune cells, but also in fibroblasts, osteoclasts, brain, lung, testis, kidney, and islets [2]. Thus, specific blockade of these channels by high affinity inhibitors may cause severe side effects and Kv1.3 channel blockers with sufficient hydrophobicity to induce apoptosis, oral applicability and good clinical tolerability are in demand. Memantine’s inhibitory effect on neuronal NMDARs was elucidated in 1989 and memantine is clinically applied in therapy of moderate to severe Alzheimer disease [38]. It is a well tolerated drug and even accidental over-dosing (until 10- fold of standard dose, i.e. 200 mg/d) showed no or only limited toxic side effects [38]. We reported that memantine blocks Kv1.3 channels on lymphocytes and leukemic cells in vitro and ex vivo and promotes concurrent inhibition of AKT/mTOR/S6, ERK1/2, and c-MYC [23], i.e. signaling pathways that are often deregulated in leukemia and are linked with particular aggressive disease and therapy resistance [39]. Furthermore, standard memantine treatment of Alzheimer patients inhibits Kv1.3 currents of lymphocytes in vivo [40], suggesting that memantine could be re-purposed for in vivo blockade of Kv1.3 channels, for instance in AraC/memantine combinatory therapies of acute leukemia. Since memantine crosses the blood-brain barrier, it could also be effective in combination with AraC in the prophylaxis or treatment of meningeosis leukemia. Besides Kv1.3 channels, memantine blocks calcium-regulated KCa3.1 potassium channels of lymphocytes [20], which could be relevant with regard to induction of resistance to Kv1.3 channel inhibitors. Given that Kv1.3 and ORAI1 subunits of CRAC channels show some structural similarities [1,7] and memantine reduces antigen receptor-induced calcium flux in lymphocytes [20,21], it can be hypothesized that memantine might also directly interfere with CRAC channel opening.


Conclusion

It has become evident that Kv1.3 channels are potent oncological targets for therapy of hematological neoplasia such as leukemia and lymphoma. The most promising Kv1.3 channel inhibitors have been psoralen derivatives like Psora-4, PAP-1 and newer generation derivatives, but clinical trials of these inhibitors are not concluded. Besides highly specific inhibitors, a number of unrelated substances have been described to inhibit Kv1.3 channels, including dexamethasone [41], diclofenac [42], statins [43-45], flavonoids [12,45], melatonin [46], SDF1α [47], human defensins [48], 18beta-glycyrrhetinic acid [49], loureirin B [50], and DPO-1 [51] (Figure 2). Some of these Kv1.3 inhibitors, like memantine, have the advantage that they are already applied in clinical therapies and thus could be tested in various drug combinations to improve treatments of hematological neoplasia. Altogether, more detailed studies are required to define the molecular mechanisms regulating Kv1.3 expression and function, for instance how Kv1.3 channels interfere with intracellular signaling pathways, like AKT or ERK1/2 activation, to modulate cellular responses and, vice versa, how different receptors and signaling molecules influence Kv1.3 channel activity. Future studies also have to verify whether re-purposed drugs like clofazimine or memantine are indeed exploitable as a potential lead compound to improve treatments in leukemia and possibly solid cancers.


Conflict of Interest

The authors declare no conflict of interest.


Funding

This work was supported by DFG grant SFB854.


References